Kinnate Biopharma Inc. (KNTE)
$3.99
Rating:
Recommendation:
-
Symbol | KNTE |
---|---|
Price | $3.99 |
Beta | 0.211 |
Volume Avg. | 0.44M |
Market Cap | 185.825M |
Shares () | - |
52 Week Range | 2.32-15.86 |
1y Target Est | - |
DCF Unlevered | KNTE DCF -> | |
---|---|---|
DCF Levered | KNTE LDCF -> | |
ROE | -65.39% | Strong Sell |
ROA | -61.06% | Strong Sell |
Operating Margin | - | |
Debt / Equity | 9.11% | Neutral |
P/E | -1.38 | Sell |
P/B | 0.79 | Buy |
Latest KNTE news
About
Download (Excel)Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.